NASDAQ:OBIO Orchestra BioMed Q2 2026 Earnings Report $4.41 -0.04 (-0.90%) Closing price 04:00 PM EasternExtended Trading$4.41 0.00 (0.00%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS-$0.38Consensus EPS -$0.39Beat/MissBeat by +$0.01One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$0.09 millionExpected Revenue$0.14 millionBeat/MissMissed by -$50.00 thousandYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Orchestra BioMed Earnings HeadlinesOrchestra BioMed Reports Q2 2026 Results and Updates Progress on BACKBEAT and Virtue Pivotal TrialsAugust 10, 2026 | quiverquant.comQOrchestra BioMed (OBIO) Expected to Announce Earnings on TuesdayAugust 9, 2026 | americanbankingnews.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.August 14 at 1:00 AM | Paradigm Press (Ad)Orchestra BioMed Hldgs Stock Dividends | NASDAQ:OBIO | BenzingaJuly 29, 2026 | benzinga.comOrchestra BioMed Holdings, Inc.July 11, 2026 | cnn.comOrchestra BioMed Joins Russell 3000® and Russell 2000® IndexesJune 29, 2026 | globenewswire.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO), Inc. (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis. Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs. The company’s development strategy emphasizes streamlined trial design and biomarker-driven patient selection, with the goal of demonstrating safety and efficacy in well-defined patient populations. In parallel, Orchestra evaluates combination approaches and seeks strategic collaborations to broaden the therapeutic reach of its candidates across multiple disease indications. Headquartered in the United States, Orchestra BioMed is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. The company operates under a governance framework committed to scientific rigor and transparent communication with investors and collaborators. Orchestra BioMed continues to build its capabilities through targeted investments in research infrastructure and external partnerships, positioning itself to address significant challenges in fibrotic, inflammatory and oncologic disease management.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
